ADMA FY 2022 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$154M+90.4% YoY

Gross Profit

$35M22.9% margin

Operating Income

-$39M-25.5% margin

Net Income

-$66M-42.8% margin

EPS (Diluted)

$-0.43

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$73M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$348M

Total Liabilities

$196M

Stockholders' Equity

$152M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$154M	$81M	+90.4%
Gross Profit	$35M	$1M	+2906.4%
Operating Income	-$39M	-$58M	+32.6%
Net Income	-$66M	-$72M	+8.0%